{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:40:25Z","timestamp":1782531625339,"version":"3.54.5"},"reference-count":38,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>INTRODUSTION: Sibutramine has been described as a drug recommended for treatment of obesity, since it has the ability to inhibit the reuptake of serotonin and noradrenaline in the central nervous system, thereby increasing energy expenditure. OBJECTIVE: Investigate the anxiogenic and anxiolytic effects of acute and chronic treatment with sibutramine in rats submitted to the task of the elevated plus-maze. METHODS: Diazepam was used as a positive control for the anxiolytic effect, and the task of the elevated plus-maze showed sensitivity to detect the effect. In the chronic treatment, sibutramine was ingested for a period of two months. RESULTS: The acute and chronic treatments at the studied dose, which is described to produce a maximum effect of anti-obesity in rats, did not interfere with anxiety. CONCLUSIONS: The acute and chronic administration of sibutramine is not related to anxiolytic or anxiogenic effects.<\/jats:p>","DOI":"10.1590\/s0004-27302010000400006","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T18:27:31Z","timestamp":1278527251000},"page":"375-380","source":"Crossref","is-referenced-by-count":7,"title":["Absence of sibutramine effect on spontaneous anxiety in rats"],"prefix":"10.1590","volume":"54","author":[{"given":"Silvana S.","family":"Frassetto","sequence":"first","affiliation":[{"name":"Universidade Luterana do Brazil, Brazil; Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isis O.","family":"Alves","sequence":"additional","affiliation":[{"name":"Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marislane M.","family":"Santos","sequence":"additional","affiliation":[{"name":"Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana E. S.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana\u00edna J.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo A.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anapaula S.","family":"Vinagre","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Pereira","sequence":"additional","affiliation":[{"name":"Ulbra, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1196\/annals.1367.017","article-title":"Serotonin and norepinephrine reuptake inhibition and eating behavior","volume":"1083","author":"Hainer V","year":"2006","journal-title":"Ann N Y Acad Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0077-8923","issn-type":"print"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/j.1550-8528.1996.tb00544.x","article-title":"A double blind randomized placebo-controlled trial of sibutramine","volume":"4","author":"Bray GA","year":"1996","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00003495-199856060-00019","article-title":"Sibutramine: A review of its contribution to the management of obesity","volume":"56","author":"Mcneely W","year":"1998","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"14","key":"ref4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00002018-200326140-00004","article-title":"A benefit-risk assessment of sibutramine in the management of obesity","volume":"26","author":"Nisoli E","year":"2003","journal-title":"Drug Saf","ISSN":"https:\/\/id.crossref.org\/issn\/0114-5916","issn-type":"print"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(24)37090-9","article-title":"In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor","volume":"283","author":"Gundlah C","year":"1997","journal-title":"J Pharmacol Exp Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/sj.bjp.0701312","article-title":"Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat","volume":"121","author":"Jackson HC","year":"1997","journal-title":"Br J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1188","issn-type":"print"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.ijo.0802062","article-title":"Mechanism of the thermogenic effect of metabolite 2 (BTS 54505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine","volume":"26","author":"Liu Y-L","year":"2002","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/oby.2002.27","article-title":"Regulation of body weight and carcass composition by sibutramine in rats","volume":"10","author":"Strack AM","year":"2002","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.pbb.2006.03.014","article-title":"Locomotion is the major determinant of sibutramine-induced increase in energy expenditure","volume":"83","author":"Golozoubova V","year":"2006","journal-title":"Pharmacol Biochem Behav","ISSN":"https:\/\/id.crossref.org\/issn\/0091-3057","issn-type":"print"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0278-5846(88)90003-6","article-title":"The pharmacology of sibutramine hydrochloride (BTS 54 524), a new anti-depressant which induces rapid noradrenergic down-regulation","volume":"12","author":"Buckett WR","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0278-5846","issn-type":"print"},{"key":"ref11","first-page":"145","article-title":"Sibutramine weight loss in depressed patients","volume":"19","author":"Kelly F","year":"1995","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"issue":"2-3","key":"ref12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(02)01423-1","article-title":"The discovery and status of sibutramine as an antiobesity drug","volume":"440","author":"Luque CA","year":"2002","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"issue":"17","key":"ref13","first-page":"18","article-title":"Mirtazapine versus selective serotonin reuptake inhibitors","volume":"60","author":"Thompson C","year":"1999","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/026988110201600202","article-title":"Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142","volume":"16","author":"Dazzi L","year":"2002","journal-title":"J Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0269-8811","issn-type":"print"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biopsych.2003.07.006","article-title":"Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity","volume":"55","author":"Vaishnavi SN","year":"2004","journal-title":"Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0091-3057(01)00701-8","article-title":"Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake: A pharmacological characterization of diverse classes of antidepressant agents","volume":"71","author":"Brocco M","year":"2002","journal-title":"Pharmacol Biochem Behav","ISSN":"https:\/\/id.crossref.org\/issn\/0091-3057","issn-type":"print"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pbb.2006.07.005","article-title":"The effects of serotonin reuptake inhibitors on locomotor activity in gerbils","volume":"85","author":"Prinssen EPM","year":"2006","journal-title":"Pharmacol Biochem Behav","ISSN":"https:\/\/id.crossref.org\/issn\/0091-3057","issn-type":"print"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1139\/y06-082","article-title":"Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors","volume":"84","author":"Frassetto SS","year":"2006","journal-title":"Can J Physiol Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0008-4212","issn-type":"print"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1248\/bpb.29.451","article-title":"Anxiolytic-like effects of (O-Methyl)- N-2,6-dihydroxybenzoyl-tyramine (Riparin III) from Aniba riparia (NEES) MEZ (Lauraceae) in Mice","volume":"29","author":"Melo CTV","year":"2006","journal-title":"Bio Pharm Bull"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjp.0702067","article-title":"A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents","volume":"125","author":"Heal DJ","year":"1998","journal-title":"Br J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1188","issn-type":"print"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/sj.ijo.0801926","article-title":"Sibutramine-dependent brown fat activation in rats: an immunohistochemical study","volume":"26","author":"Giordano A","year":"2002","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"issue":"1","key":"ref22","first-page":"18","article-title":"Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine","volume":"22","author":"Heal DJ","year":"1998","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjp.0702633","article-title":"Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats","volume":"127","author":"Grignaschi G","year":"1999","journal-title":"Br J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1188","issn-type":"print"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open: closed arms entries in an elevated plus-maze as a measure of anxiety in the rat","volume":"14","author":"Pellow S","year":"1985","journal-title":"J Neurosci Methods","ISSN":"https:\/\/id.crossref.org\/issn\/0165-0270","issn-type":"print"},{"key":"ref25","series-title":"Ethology and psychopharmacology","first-page":"9","volume-title":"The elevated plus-maze: pharmacology, methodology and ethology","author":"Rodgers RJ","year":"1994"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11064-006-9050-x","article-title":"Effects of milnacipran in animal models of anxiety and memory","volume":"31","author":"Moojen VKM","year":"2006","journal-title":"Neurochem Res","ISSN":"https:\/\/id.crossref.org\/issn\/0364-3190","issn-type":"print"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbr.2006.10.002","article-title":"Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze","volume":"176","author":"Drapier D","year":"2007","journal-title":"Behav Brain Res","ISSN":"https:\/\/id.crossref.org\/issn\/0166-4328","issn-type":"print"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0163-7258(00)00083-8","article-title":"The psychobiology of anxiolytic drugs: Part 2: pharmacological treatments of anxiety","volume":"88","author":"Argyropoulos SV","year":"2000","journal-title":"Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0163-7258","issn-type":"print"},{"issue":"1-2","key":"ref29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.09.043","article-title":"Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm","volume":"504","author":"Miyamoto J","year":"2004","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00213-002-1111-5","article-title":"Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats","volume":"162","author":"Mochizuki D","year":"2002","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(87)90101-5","article-title":"Animal models of anxiety: the effects of compounds that modify 5-HT neurotransmission","volume":"8","author":"Chopin P","year":"1987","journal-title":"Trends Pharmacol Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0165-6147","issn-type":"print"},{"issue":"6","key":"ref32","first-page":"5","article-title":"Serotonin receptor specificity in anxiety disorders","volume":"57","author":"Lucki I","year":"1996","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(95)98597-J","article-title":"5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research","volume":"65","author":"Griebel G","year":"1995","journal-title":"Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0163-7258","issn-type":"print"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0163-7258(95)00004-Z","article-title":"5-Hydroxytryptamine pathways in anxiety and its treatment","volume":"66","author":"Handley SL","year":"1995","journal-title":"Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0163-7258","issn-type":"print"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/NMM:5:1:027","article-title":"The serotonergic system and anxiety","volume":"5","author":"Gordon JA","year":"2004","journal-title":"Neuromol Med"},{"issue":"22","key":"ref36","first-page":"12","article-title":"The functional anatomy, neurochemistry, and pharmacology of anxiety","volume":"60","author":"Ninan PT","year":"1999","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants","volume":"10","author":"Stahl SM","year":"2005","journal-title":"CNS Spectr"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.phrs.2004.05.003","article-title":"Effects of sibutramine on anxiety-related behaviours in rats","volume":"50","author":"Jorge SD","year":"2004","journal-title":"Pharmacol Res","ISSN":"https:\/\/id.crossref.org\/issn\/1043-6618","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v54n4\/a06v54n4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T19:10:46Z","timestamp":1740251446000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302010000400006&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0004-27302010000400006"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302010000400006","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}